Scientists from The Scripps Research Institute, Scripps Health, and collaborating cancer physicians have successfully demonstrated the effectiveness of an advanced blood test for detecting and analyzing circulating tumor cells (CTCs) - breakaway cells from patients’ solid tumors - from cancer patients…
More: continued here
Filed under: Prostate on February 9th, 2012 | No Comments »
Research led by Wanguo Liu, PhD, Associate Professor of Genetics at LSU Health Sciences Center New Orleans, has identified a new protein critical to the development and growth of prostate cancer. The findings are published online in the Early Edition of Proceedings of the National Academy of Sciences, available the week of February 6, 2012. […]
Filed under: Prostate on February 9th, 2012 | No Comments »
A new study by NYU Langone Medical Center and Northwestern University Feinberg School of Medicine shows novel PSA velocity (PSAV) risk count testing may provide a more effective way for physicians to screen men for clinically significant prostate cancer…
More: continued here
Filed under: Prostate on February 6th, 2012 | No Comments »
Initial results of a multicenter study coordinated by researchers at Fred Hutchinson Cancer Research Center indicates that two investigational urine-based biomarkers are associated with prostate cancers that are likely to be aggressive and potentially life-threatening among men who take a “watchful waiting,” or active-surveillance approach to manage their disease…
More: continued here
Filed under: Prostate on February 6th, 2012 | No Comments »
A new drug, MDV3100, is improving the survival rate in men with advanced prostate cancer, results of a large, phase III clinical trial show. The drug is designed to block a type of cellular receptor that drives progression of prostate cancer…
More: continued here
Filed under: Prostate on February 3rd, 2012 | No Comments »
Research on promising new therapies and data on the relative benefits of established treatments for prostate cancer have been released, in advance of the fourth annual Genitourinary Cancers Symposium, being held February 2-4, 2012, at the San Francisco Marriott Marquis in San Francisco, Calif…
More: continued here
Filed under: Prostate on February 3rd, 2012 | No Comments »
Brachytherapy for high-risk prostate cancers patients has historically been considered a less effective modality, but a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests otherwise…
More: continued here
Filed under: Prostate on January 30th, 2012 | No Comments »
According to a study from radiation oncologists at the Kimmel Cancer Center at Jefferson, high-risk prostate cancer patients who receive brachytherapy, alone or together with external beam radiation therapy (EBRT) had considerably lower mortality rates. The study is published online January 23 in the International Journal of Radiation Oncology*Biology*Physics…
More: continued here
Filed under: Prostate on January 30th, 2012 | No Comments »
According to Beth Israel Deaconess Medical Center and prostate expert Marc B. Garnick, MD, physicians who advise PSA tests for men being screened for prostate cancer must base their decision more on available evidence when recommending screening, biopsies and treatments, instead of holding on to long held beliefs that PSA-based testing benefits all…
More: continued […]
Filed under: Prostate on January 26th, 2012 | No Comments »
A study published Online First in The Lancet has found that a common medication (dutasteride) used to treat enlargement of the prostate, may also reduce the need for treatments that pose risks of incontinence and impotence and delay growth of early-stage prostate cancer…
More: continued here
Filed under: Prostate on January 25th, 2012 | No Comments »